News from pharmacyclics, inc

Jun 09, 2014, 08:00 ET

Supplemental New Drug Application for IMBRUVICA® Accepted by the U.S. FDA and Priority Review Granted

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New...

May 31, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients with CLL

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA® (ibrutinib) will be featured in...

May 31, 2014, 08:05 ET
May 31, 2014, 08:05 ET

IMBRUVICA® (ibrutinib) Combination with anti CD20 Antibody Shows Compelling Results in Heavily Pretreated Patients with CLL and Related Diseases

 Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that IMBRUVICA®(ibrutinib) in combination with the anti-CD20 antibody, ofatumumab,...

May 20, 2014, 08:00 ET

Pharmacyclics appoints Gregory R. Wade to lead Business Development

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice...

May 14, 2014, 18:22 ET

Pharmacyclics Highlights Important New Data for IMBRUVICA® (ibrutinib) in B-Cell Malignancies

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced IMBRUVICA® (ibrutinib) will be featured in ten abstracts, including both company-sponsored...

May 02, 2014, 08:00 ET

Pharmacyclics Reports First Quarter 2014 Results

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended March 31,...

Apr 25, 2014, 10:45 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for First Quarter of 2014

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...

Apr 21, 2014, 11:45 ET

Pharmacyclics Announces Presentation of Phase III and Long Term Follow Up Data on IMBRUVICA™ in Chronic Lymphocytic Leukemia (CLL) at ASCO

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that data from the Phase III PCYC-1112 (RESONATE™) study of single agent...

Apr 08, 2014, 08:00 ET

Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA with Phase III CLL Study Data

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug...

Feb 20, 2014, 16:01 ET

Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December...

Feb 14, 2014, 15:45 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Fourth Quarter and Year End 2013

 Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...

Feb 12, 2014, 13:18 ET

U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib)...

Jan 07, 2014, 09:30 ET
Dec 10, 2013, 17:19 ET

Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib...

Dec 09, 2013, 19:01 ET

Ibrutinib Frontline Chronic Lymphocytic Leukemia Study Results Published in The Lancet Oncology

 Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that The Lancet Oncology published results of a study evaluating ibrutinib in previously...

Nov 13, 2013, 12:41 ET

U.S. Food and Drug Administration Approves IMBRUVICA™ (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) as a...

Nov 07, 2013, 16:33 ET

Pharmacyclics Reports Third Quarter 2013 Results

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter ended September 30,...

Nov 01, 2013, 18:47 ET

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013

Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today announced that it will hold a conference call and audio webcast to discuss financial...

Aug 29, 2013, 06:30 ET

New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA

Pharmacyclics, Inc. (Nasdaq: PCYC) today announced that the U.S. Food and Drug Administration (FDA)  has accepted for filing its New Drug...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer